CRP and depressive symptom measurement: In the omalizumab group, there was also a very significant reduction in the levels of UAS7 (p < 0.001) and a significant reduction in the Anxiety Scale, ESR and DLQI (p < 0.01) after therapy, but no significant decrease in the depression scale and CRP (p > 0.05).